Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 2
1972 1
1973 1
1974 1
1975 1
1985 1
1993 3
1994 2
1995 2
1997 1
1998 2
1999 3
2000 1
2001 3
2002 4
2003 5
2004 3
2005 4
2006 3
2007 5
2008 7
2009 7
2010 4
2011 5
2012 8
2013 2
2014 4
2015 7
2016 7
2017 8
2018 7
2019 3
2020 3
2021 5
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological treatment of Parkinson disease: a review.
Connolly BS, Lang AE. Connolly BS, et al. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. JAMA. 2014. PMID: 24756517 Review.
Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life. OBJECTIVE: To provide an evidence-based review of the initial pharmacological management of the classic motor symptoms of Parkinson di …
Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life. O …
The use of memantine in neuropsychiatric disorders: An overview.
Lu S, Nasrallah HA. Lu S, et al. Ann Clin Psychiatry. 2018 Aug;30(3):234-248. Ann Clin Psychiatry. 2018. PMID: 30028898 Review.
RESULTS: Memantine monotherapy was found to exert efficacy in several neuropsychiatric conditions, including autism spectrum disorder, binge eating disorder, and attention-deficit/hyperactivity disorder. ...For schizophrenia, memantine has been reported to be …
RESULTS: Memantine monotherapy was found to exert efficacy in several neuropsychiatric conditions, including autism spectrum disorder …
Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials.
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Raupp-Barcaro IF, et al. Braz J Psychiatry. 2018 Oct-Dec;40(4):449-458. doi: 10.1590/1516-4446-2017-2393. Epub 2018 Jun 11. Braz J Psychiatry. 2018. PMID: 29898194 Free PMC article. Review.
We conducted a systematic review of preclinical and clinical studies addressing the effects of amantadine in animal models of depression and in patients with depression. ...CONCLUSION: Amantadine is an interesting candidate as new antidepressant …
We conducted a systematic review of preclinical and clinical studies addressing the effects of amantadine in animal models of …
LRRK2 Parkinson Disease.
Saunders-Pullman R, Raymond D, Elango S. Saunders-Pullman R, et al. 2006 Nov 2 [updated 2023 Jul 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2006 Nov 2 [updated 2023 Jul 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301387 Free Books & Documents. Review.
Certain nonmotor symptoms in LRRK2-PD, especially REM sleep behavior disorder and cognitive decline, may occur at similar or slightly reduced frequency compared to typical idiopathic* PD. ...Dopamine agonists may also be used, as well as monoamine oxidase-B (MAO-B) inhibit …
Certain nonmotor symptoms in LRRK2-PD, especially REM sleep behavior disorder and cognitive decline, may occur at similar or slightly …
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. Seppi K, et al. Mov Disord. 2011 Oct;26 Suppl 3(0 3):S42-80. doi: 10.1002/mds.23884. Mov Disord. 2011. PMID: 22021174 Free PMC article. Review.
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of …
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease ( …
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Furlan A, Sgrignani J, Locatelli P, Cavalli A, O'Gorman C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL. Fava M, et al. Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1463-1476. doi: 10.1007/s00406-023-01571-4. Epub 2023 Mar 8. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36890259 Free PMC article. Review.
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have …
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. …
VPS35-Related Parkinson Disease.
Dulski J, Ross OA, Wszolek ZK. Dulski J, et al. 2017 Aug 10 [updated 2023 Mar 23]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2017 Aug 10 [updated 2023 Mar 23]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 28796472 Free Books & Documents. Review.
Dyskinesia and motor fluctuations may occur. Neuropsychiatric manifestations (depression and schizophrenia), learning difficulties, mild cognitive impairment, and dementia have been reported, albeit with lower occurrence than in simplex Parkinson disease of unknown cause. …
Dyskinesia and motor fluctuations may occur. Neuropsychiatric manifestations (depression and schizophrenia), learning difficulties, m …
Possible use of amantadine in depression.
Huber TJ, Dietrich DE, Emrich HM. Huber TJ, et al. Pharmacopsychiatry. 1999 Mar;32(2):47-55. doi: 10.1055/s-2007-979191. Pharmacopsychiatry. 1999. PMID: 10333162 Review.
Amantadine appears to act through several pharmacological mechanisms, none of which has been identified as the one chief mode of action. ...Additionally, animal studies as well as clinical trials in humans have hinted at an antidepressant activity of amantadine. We …
Amantadine appears to act through several pharmacological mechanisms, none of which has been identified as the one chief mode of acti …
A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use.
Yeh PG, Spruyt K, DelRosso LM, Walters AS. Yeh PG, et al. Tremor Other Hyperkinet Mov (N Y). 2023 Mar 2;13:7. doi: 10.5334/tohm.739. eCollection 2023. Tremor Other Hyperkinet Mov (N Y). 2023. PMID: 36873914 Free PMC article. Review.
However, in clinical practice, treatment is sometimes limited due to incomplete response or side effects and it is necessary to be aware of other treatment options for RLS, which is the purpose of this review. METHODS: We performed a narrative review detailing all o …
However, in clinical practice, treatment is sometimes limited due to incomplete response or side effects and it is necessary to be aware of …
INCOG 2.0 Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed.
Ponsford J, Velikonja D, Janzen S, Harnett A, McIntyre A, Wiseman-Hakes C, Togher L, Teasell R, Kua A, Patsakos E, Welch-West P, Bayley MT. Ponsford J, et al. J Head Trauma Rehabil. 2023 Jan-Feb 01;38(1):38-51. doi: 10.1097/HTR.0000000000000839. J Head Trauma Rehabil. 2023. PMID: 36594858
METHODS: An expert panel of clinicians/researchers (known as INCOG) reviewed evidence published from 2014 and developed updated guidelines for the management of attention in adults, as well as a decision-making algorithm, and an audit tool for review of clinical practice. …
METHODS: An expert panel of clinicians/researchers (known as INCOG) reviewed evidence published from 2014 and developed updated guidelines f …
127 results